# Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies

> **NCT01613261** · PHASE1 · WITHDRAWN · sponsor: **Millennium Pharmaceuticals, Inc.**

## Conditions studied

- Advanced Nonhematologic Malignancies

## Interventions

- **DRUG:** TAK-733 and alisertib

## Key facts

- **NCT ID:** NCT01613261
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-08
- **Primary completion:** 2015-09
- **Final completion:** 2015-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01613261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01613261, "Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01613261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*